Zobrazeno 1 - 10
of 2 248
pro vyhledávání: '"Tumor xenograft"'
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4661-4679 (2024)
Puhua Wu,1,2 Zhicheng Zhang,1 Yan Zhou,2 Quan Liu,2 Kin-Yip Tam,2 Zhenhong Su1 1Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, School of Medicine, Hubei Polytechnic University, Huangshi, People’s Republic of China; 2Cancer C
Externí odkaz:
https://doaj.org/article/2422995ba4a944debc9122fc0cd45596
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 18, Pp 4481-4483 (2024)
Zhu Y, Cheng M, Yang Z, et al. Drug Des Devel Ther. 2014;8:2449–2462. The authors have advised that figure parts 2E and 4B on pages 2454 and 2456, respectively, are incorrect. An error at the time of figure assembly led to the inadvertent duplicati
Externí odkaz:
https://doaj.org/article/2bb1603102b04ac2bfb215c516986e5b
Publikováno v:
Journal of Functional Foods, Vol 122, Iss , Pp 106460- (2024)
Glyceollins are soy-derived phytoalexins that have been proposed as candidate compounds for the prevention of prostate cancer. The present study tested the efficacies of glyceollins on prostate cancer prevention in-vitro and in-vivo. In-vitro, glyceo
Externí odkaz:
https://doaj.org/article/1e160f3e0be9411fb431ee318544f259
Autor:
Alessia Formato, Maria Salbini, Elisa Orecchini, Manuela Pellegrini, Mariachiara Buccarelli, Lucia Ricci Vitiani, Stefano Giannetti, Roberto Pallini, Quintino Giorgio D'Alessandris, Liverana Lauretti, Maurizio Martini, Valentina De Falco, Andrea Levi, Maria Laura Falchetti, Maria Patrizia Mongiardi
Publikováno v:
Cancer Medicine, Vol 13, Iss 19, Pp n/a-n/a (2024)
ABSTRACT Objective Axitinib is a tyrosine kinase inhibitor characterized by a strong affinity for Vascular Endothelial Growth Factor Receptors (VEGFRs). It was approved in 2012 by Food and Drug Administration and European Medicines Agency as a second
Externí odkaz:
https://doaj.org/article/7cc7cde955aa431da8a4db85e35cb3d3
Autor:
Masanori Ozaki, Ken Kageyama, Kenjiro Kimura, Shinpei Eguchi, Akira Yamamoto, Ryota Tanaka, Takehito Nota, Hiroki Yonezawa, Hideyuki Nishiofuku, Yuki Sakai, Naoki Tani, Atsushi Jogo, Mizue Terai, Takami Sato, Takeaki Ishizawa, Yukio Miki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Liver metastases from pancreatic ductal adenocarcinoma (PDAC) are highly fatal. A rat-based patient-derived tumor xenograft (PDX) model is available for transcatheter therapy. This study aimed to create an immunodeficient rat model with live
Externí odkaz:
https://doaj.org/article/a062ad6132a74f5f94005ead20d308ed
Publikováno v:
Shanghai Jiaotong Daxue xuebao. Yixue ban, Vol 44, Iss 4, Pp 435-443 (2024)
Objective·To establish a patient-derived tumor xenograft (PDX) model using tumor cells sourced from malignant pleural effusion (MPE) in patients with lung cancer, and to conduct experimental validation.Methods·Gene expression data were downloaded f
Externí odkaz:
https://doaj.org/article/3154cd54e811497ab87555d4cf9ea723
Autor:
Xiaojie Chu, Seungmin Shin, Du-San Baek, Liyong Zhang, Alex Conard, Megan Shi, Ye-Jin Kim, Cynthia Adams, Maggie Hines, Xianglei Liu, Chuan Chen, Zehua Sun, Dontcho V. Jelev, John W. Mellors, Dimiter S. Dimitrov, Wei Li
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Prostate stem cell antigen (PSCA) is expressed in all stages of prostate cancer, including in advanced androgen-independent tumors and bone metastasis. PSCA may associate with prostate carcinogenesis and lineage plasticity in prostate cancer. PSCA is
Externí odkaz:
https://doaj.org/article/1f085d6811ce4dcda8bde14f50a5302f
Publikováno v:
Journal of Pharmacological Sciences, Vol 152, Iss 2, Pp 69-75 (2023)
Objective: AST-3424 is a novel specific aldo-keto reductase 1C3 (AKR1C3) prodrug that releases a DNA alkylating reagent upon reduction by AKR1C3. This study aimed to evaluate the efficacy and safety of AST-3424 in patient-derived tumor xenograft (PDT
Externí odkaz:
https://doaj.org/article/4be4ad79cff343dc8b0d7602b9af2104
Autor:
Marshall D. Behrens, Robert J. Stiles, Gennett M. Pike, Laura A. Sikkink, Yongxian Zhuang, Jia Yu, Liewei Wang, Judy C. Boughey, Matthew P. Goetz, Mark J. Federspiel
Publikováno v:
Molecular Therapy: Oncolytics, Vol 27, Iss , Pp 239-255 (2022)
Historically, the clinical utility of oncolytic virotherapy as a treatment for a wide range of cancer types was first demonstrated by three pilot human clinical trials conducted in Japan in the 1970s and 1980s using a wild-type Urabe mumps virus (MuV
Externí odkaz:
https://doaj.org/article/b9ed91b0cb974385bc37be3b4a346fb0
Autor:
Yong-Hee Cho
Publikováno v:
Current Issues in Molecular Biology, Vol 44, Iss 11, Pp 5352-5362 (2022)
Intensive efforts to develop anti-cancer agents have been made for over 60 years. However, cancer is still considered a lethal disease. To study the best anti-cancer agents for improving the survival rates of cancer patients, many researchers have fo
Externí odkaz:
https://doaj.org/article/255f40c8c5f74fb5b5745a0251141480